Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)

Trial Profile

Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 19 May 2017

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HTLV-I infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
    • 02 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
    • 02 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top